A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

This study is testing whether adding an immunotherapy drug called tislelizumab to standard chemoradiation (chemotherapy combined with radiation) works better as a first-line treatment for people with advanced esophageal squamous cell carcinoma — cancer of the squamous cells lining the food pipe — that has low levels of a protein called PD-L1. **You may be eligible if:** - You have been diagnosed with squamous cell carcinoma of the esophagus, confirmed by biopsy - Your cancer is advanced, recurrent, or has spread and cannot be cured with surgery or radiation alone - Your tumor has low PD-L1 expression (CPS score below 10) - You have not received prior systemic (whole-body) anti-cancer treatment for your advanced disease - You have at least one measurable tumor on imaging - You are in good enough physical health to undergo treatment (ECOG performance status 0 or 1) **You may NOT be eligible if:** - You have active or symptomatic brain or spinal cord metastases - You have an active autoimmune disease - You have HIV, active hepatitis B, or active hepatitis C - You have previously received immunotherapy drugs (anti-PD-1, anti-PD-L1, anti-CTLA-4, etc.) - You have serious uncontrolled medical conditions or active infections Talk to your doctor to see if this trial is right for you.